Target Price | $98.61 |
Price | $81.53 |
Potential | 20.95% |
Number of Estimates | 23 |
23 Analysts have issued a price target DexCom, Inc. 2026 . The average DexCom, Inc. target price is $98.61. This is 20.95% higher than the current stock price. The highest price target is $115.00 41.05% , the lowest is $82.00 0.58% . | |
A rating was issued by 29 analysts: 24 Analysts recommend DexCom, Inc. to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2026 of 20.95% . Most analysts recommend the DexCom, Inc. stock at Purchase. |
24 Analysts have issued a sales forecast DexCom, Inc. 2025 . The average DexCom, Inc. sales estimate is $4.6b . This is 11.20% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.7b 13.39% , the lowest is $4.6b 10.13% .
This results in the following potential growth metrics:
2024 | $4.0b | 11.34% |
---|---|---|
2025 | $4.6b | 14.37% |
2026 | $5.3b | 15.41% |
2027 | $6.1b | 14.64% |
2028 | $7.1b | 16.15% |
2029 | $7.8b | 10.48% |
13 Analysts have issued an DexCom, Inc. EBITDA forecast 2025. The average DexCom, Inc. EBITDA estimate is $1.4b . This is 59.36% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.4b 62.28% , the lowest is $1.2b 44.09% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $818m | 4.34% |
---|---|---|
2025 | $1.4b | 67.17% |
2026 | $1.7b | 23.14% |
2027 | $2.0b | 21.43% |
2028 | $2.5b | 22.59% |
2029 | $2.9b | 14.54% |
2024 | 20.28% | 6.29% |
---|---|---|
2025 | 29.64% | 46.19% |
2026 | 31.62% | 6.68% |
2027 | 33.50% | 5.95% |
2028 | 35.35% | 5.52% |
2029 | 36.65% | 3.68% |
13 DexCom, Inc. Analysts have issued a net profit forecast 2025. The average DexCom, Inc. net profit estimate is $766m . This is 46.82% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $798m 53.05% , the lowest is $721m 38.35% .
This results in the following potential growth metrics and future Net Margins:
2024 | $557m | 9.23% |
---|---|---|
2025 | $766m | 37.51% |
2026 | $994m | 29.82% |
2027 | $1.2b | 25.70% |
2028 | $1.6b | 26.08% |
2029 | $1.8b | 11.84% |
2024 | 13.81% | 1.89% |
---|---|---|
2025 | 16.60% | 20.24% |
2026 | 18.67% | 12.47% |
2027 | 20.47% | 9.64% |
2028 | 22.23% | 8.60% |
2029 | 22.50% | 1.21% |
13 Analysts have issued a DexCom, Inc. forecast for earnings per share. The average DexCom, Inc. EPS is $1.95 . This is 46.62% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.04 53.38% , the lowest is $1.84 38.35% .
This results in the following potential growth metrics and future valuations:
2024 | $1.42 | 9.23% |
---|---|---|
2025 | $1.95 | 37.32% |
2026 | $2.54 | 30.26% |
2027 | $3.19 | 25.59% |
2028 | $4.02 | 26.02% |
2029 | $4.49 | 11.69% |
Current | 61.20 | 26.15% |
---|---|---|
2025 | 41.75 | 31.78% |
2026 | 32.16 | 22.97% |
2027 | 25.59 | 20.43% |
2028 | 20.29 | 20.71% |
2029 | 18.14 | 10.60% |
Based on analysts' sales estimates for 2025, the DexCom, Inc. stock is valued at an EV/Sales of 6.91 and an P/S ratio of 6.93 .
This results in the following potential growth metrics and future valuations:
Current | 7.68 | 42.47% |
---|---|---|
2025 | 6.91 | 10.09% |
2026 | 5.98 | 13.35% |
2027 | 5.22 | 12.77% |
2028 | 4.49 | 13.90% |
2029 | 4.07 | 9.49% |
Current | 7.71 | 42.61% |
---|---|---|
2025 | 6.93 | 10.07% |
2026 | 6.01 | 13.35% |
2027 | 5.24 | 12.77% |
2028 | 4.51 | 13.90% |
2029 | 4.08 | 9.49% |
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | May 05 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | May 02 2025 |
Baird |
Outperform
➜
Outperform
|
Unchanged | May 02 2025 |
Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | May 02 2025 |
Mizuho |
➜
Outperform
|
Initiated | Apr 10 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Mar 04 2025 |
Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Feb 14 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
May 05 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
May 02 2025 |
Unchanged
Baird:
Outperform
➜
Outperform
|
May 02 2025 |
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
May 02 2025 |
Initiated
Mizuho:
➜
Outperform
|
Apr 10 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Mar 04 2025 |
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Feb 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.